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Abstract
Several human diseases including neurodegenerative disorders and cancer are associated with abnormal accumulation and
aggregation of misfolded proteins. Proteins with high tendency to aggregate include the p53 gene product, TAU and alpha
synuclein. The potential toxicity of aberrantly folded proteins is limited via their transport into intracellular sub-
compartments, the aggresomes, where misfolded proteins are stored or cleared via autophagy. We have identified a region
of the acetyltransferase p300 that is highly disordered and displays similarities with prion-like domains. We show that this
region is encoded as an alternative spliced variant independently of the acetyltransferase domain, and provides an
interaction interface for various misfolded proteins, promoting their aggregation. p300 enhances aggregation of TAU and of
p53 and is a component of cellular aggregates in both tissue culture cells and in alpha-synuclein positive Lewy bodies of
patients affected by Parkinson disease. Down-regulation of p300 impairs aggresome formation and enhances cytotoxicity
induced by misfolded protein stress. These data unravel a novel activity of p300, offer new insights into the function of
disordered domains and implicate p300 in pathological aggregation that occurs in neurodegeneration and cancer.
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Introduction
Intrinsically disordered proteins (IDPs) are hallmarked by the
lack of stable tertiary structure under physiological conditions
in vitro and in vivo, and are increasingly recognized as therapeutic
targets [1,2]. These proteins are very abundant in nature and are
proposed to play a physiological role in many biological processes,
including transcription and signaling. However, there is also a
clear connection between human diseases and protein intrinsic
disorder. In the nervous system, several IDPs can acquire stable
aberrant conformations becoming aggregation prone and accu-
mulating in the nucleus, cytoplasm or extra-cellular spaces of
affected cells, forming distinctive inclusion bodies or fibrillar
amyloid [3,4,5]. a-Synuclein, TAU and p53 are prototype
examples of proteins with an intrinsically disordered conformation
that accumulate in neurodegenerative diseases or that are involved
in cancer pathogenesis [1,3,4,6].
Cytoplasmic inclusions that resemble pathological aggregates
seen in neurodegenerative disorders also form in cultured cells
when the proteasome is inhibited. These cytoplasmic organelles
are known as aggresomes and exhibit well-defined structure and
dynamics [7]. Aggresomes assemble by retrograde transport of
misfolded proteins towards the minus end of microtubules, and
localize in a specific area of the cell, close to the nucleus and
around the microtubule organizing center. This process requires
the molecular motor dynein and the deacetylase HDAC6 that
act by escorting misfolded poly-ubiquitinated proteins to
aggresomes [8,9]. First identified in the characterization of a
mutant form of the cystic fibrosis trans-membrane conducting
regulator CFTR-DF508 [10], aggresomes also generate a site for
replication of various viruses, including Epstein–Barr virus,
EBV, and Human Papilloma Virus [11]. Aggresomes form
when cells are overwhelmed by misfolded proteins that
accumulate due to impairment of proteasomal activity or
Endoplasmic Reticulum (ER) stress [9]. Additionally, misfolding
and aggregation of many proteins can occur via post-transla-
tional modifications, alternative splicing, mutations, or oxidative
stress [8].
A question that has attracted the attention of many studies
pertains to the effects of aggresome formation on cell survival.
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The original hypothesis of a direct cytotoxicity exerted by
protein aggregates has been challenged by several lines of
evidence, including the observation that loss of function of the
ubiquitin ligase Ube3 in SCA1 mice increases neurodegenera-
tion while decreasing the extent of nuclear aggregates [12].
Similarly, expression of HDAC6, which is necessary for
aggresome formation, rescues degeneration caused by proteo-
lytic dysfunction in a drosophila melanogaster model of spinobulbar
muscular atrophy [13]. These and relayed observations suggest
that inclusion bodies might have a cytoprotective effect, acting
by either directing misfolded proteins for disruption via the
autophagic machinery or by simply sequestering them from the
cytoplasm thus preventing their toxicity [14]. In this latter
instance, the sequestration of misfolded proteins into aggresomes
reduces their ability to aberrantly interact with other proteins
and removes them from sites of action, in the case of the
nervous system, from nerve terminals [9]. Consistent with this
protective effect, inhibition of aggresome formation leads to
decreased cell viability, and targeting of this process has been
proposed as a therapeutic strategy especially in the treatment of
cancer [14]. For example, the anti-tumor activity of the
proteasome inhibitor, bortezomib, is significantly enhanced
when used in combination with HDAC6 inhibitors [9,15].
However, there is still limited knowledge about the molecular
components of aggresomes and their identification might have
implications for the understanding of diseases characterized by
protein misfolding.
p300 and its homolog CBP, play an important role in the
execution of multiple biological programs, such as differentiation,
senescence and apoptosis [16,17]. Most, -if not all- of the activities
attributed to these proteins take place in the nucleus, via regulation
of transcription and promotion of acetylation of many factors,
including histones. In this study, we identify a novel cytoplasmic
activity of p300 unrelated to its acetyltransferase function, and
residing in an intrinsically disordered domain with similarities to
prion-like domains. Through this region p300 provides an
interaction platform for various proteins, including TAU and
p53, inducing their aggregation. Our findings unravel a direct role
of p300 in aggregation and provide an example of how disordered
domains participate in biological processes relevant to human
diseases.
Results
p300 Localizes in Aggresomes and in Lewy Bodies of
Parkinson’s Disease
Inhibition of the activity of the proteasome results in accumu-
lation of misfolded ubiquitinated proteins that are segregated into
aggresomes [7,8,9]. It was previously shown that p300 can
associate with ubiquitinated protein species, but it was not clear
whether such association occurs in the nucleus or in the cytoplasm
[18,19,20]. Therefore we studied the localization of p300 and
ubiquitin in cells where the global levels of ubiquitinated proteins
are increased due to treatment with the proteasome inhibitor
MG132. In untreated Cos7 cells, p300 was detectable predom-
inantly in the nucleus, as expected, but also in the cytoplasmic
compartment and p300 and ubiquitin did not overtly co-localize
(Figure 1A). Following MG132 treatment however, a significant
fraction of p300 collapsed into aggresomes in a juxta-nuclear
position, where it co-localized with both ubiquitin and vimentin
(Figure 1, compare panels B and C with panel A). Indeed, the
majority of the aggresomes formed in the presence of MG132
contained p300 (Figure 1D). To determine whether this pattern
of aggresome localization is cell type specific, we expanded these
experiments to other cell lines. p300 was present in aggresomes in
the lung cancer cell line H1299 and in human embryonic kidney
Hek293 cells (Figures S1A and S1B). To then confirm the
association with aggresomes detected in immuno-fluorescence, we
asked whether p300 forms soluble protein-protein complexes with
various known components of these organelles. These experiments
showed that p300 interacts with two important constituents of
aggresomes, specifically with the cellular motor protein dynein and
with HDAC6 (Figure 1E) [8]. Interestingly, a similar cytoplasmic
pattern of localization could not be clearly seen in the case of CBP,
in spite of the high degree of homology between these two proteins
(Figure S2).
Aggresomes share similarities with various pathological
inclusion bodies in terms of their structure and composition,
particularly with Lewy Bodies (LB), which are characteristic of
neurodegenerative disorders such as Parkinson Disease (PD) and
dementia [8,21,22]. Therefore to determine whether p300 can
be detected in these types of aggregates we performed immuno-
staining of brain sections derived from patients affected by PD
or of normal control brains. In the brain of PD patients, Lewy
Bodies are identified as large inclusions characterized by the
presence of alpha-synuclein, ubiquitin and HDAC6 [8]. While
p300 was undetectable in sections derived from normal brains
(Figure 2A), in the midbrain of PD patients it formed distinct
large aggregates that either surrounded (Figure 2B) or co-
localized (Figure 2C) with pathognomonic a-synuclein positive
inclusions. Significantly, similarly to what we observed in tissue
culture cells, p300 also co-localized with ubiquitin and with
HDAC6 in the LBs of affected patients (Figure 2D and
Figure 2E).
Thus, p300 is a component of aggresomes and of pathological
aggregates typical of Parkinson Disease.
The C-terminus of p300 is Necessary for p300
Localization into Aggresomes
p300 is a large protein with multiple functional domains
(depicted in Figure 3A) [16]. There are three histidine rich motifs
in p300, named CH1, CH2 and CH3, each containing zinc-
fingers domains (ZNFs) with different structural and functional
characteristics. The region comprising the CH1 is well character-
ized and possess an E4-ubiquitin elongating activity that aids in the
degradation of p53 [19,20,23]. The CH3 encompasses two
structurally distinct zinc fingers (ZNF) the function of which has
not been entirely elucidated. The first ZNF, ZNF-ZZ spans
between amino acids 1684–1703, while the second, ZNF-TAZ2, is
comprised between amino acid 1723–1836. The histone acetyl-
transferase domain (HAT) maps to a large central fragment of the
protein, with the core segment comprised between amino acids
1284–1669. To determine what region of p300 is involved in the
association with aggresomes we examined the localization pattern
of several deletion mutants differing for the presence or absence of
these structural motifs (quantified in Figure 3B and shown as
representative immuno-fluorescence data in Figure 3C). As
shown previously, full-length p300 was detected in aggresomes.
By contrast a p300 N-terminal fragment containing the first CH1
and encompassing the previously identified E4-ubiquitin domain
(p300-N) was never found in the cytoplasmic compartment nor
was it localized in aggresomes. Therefore, the association of p300
with aggresomes and ubiquitin that we observed previously is
independent of this domain. Consistent with this interpretation, a
p300 deletion mutant possessing the CH1 but lacking the
acetyltransferase domain and the first ZN-FF zinc finger within
the CH3 (p300 D242–1737) displayed impaired localization into
aggresomes, and a nearly full-length p300 protein with a small
p300 Regulates the Fate of Misfolded Proteins
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deletion of the second zinc finger in the CH3, TAZ2 (p300-D30,
or D1737–1809), was found in these organelles to a significant
lesser extent compared to native p300. Finally, a p300 protein
encompassing the entire CH3 and most of the p300 C-terminus
(from amino acids 1514 to 1922, referred to as CH3-CTD),
efficiently localized into aggresomes (Figure 3B), thus suggesting
that this domain might be responsible for routing p300 into these
organelles.
The C-terminus of p300 is a Disordered Domain with
Similarities to Prion-like Domains
The above findings prompted us to ask whether the p300 C-
terminus possesses distinguishable structural motifs common to
other proteins involved in protein aggregation. A BLAST search of
the p300 amino acid sequences encompassing amino acid residues
1688 to 2414 revealed the existence of a significant homology with
various prion-like proteins expressed in various species, including
C. elegans, which aligned with p300 with a highly significant Blast e-
Figure 1. p300 localizes in aggresomes. A–C. Cos7 cells were treated with DMSO (A) or treated with 5 mM MG132 for 16 hours (B–C) and cells
were stained with a monoclonal mix of anti-ubiquitin (A and B), the anti-p300 polyclonal C20 antibody (A–C), or anti-vimentin monoclonal (C)
antibodies (see materials and methods for details on the antibodies). The arrow in panel A, indicates the presence of p300 in diffused cytoplasmic
aggregates. The arrows in B and C indicate the position of representative aggresomes, enclosed by vimentin and containing ubiquitin. Cells were
subjected to fluorescence deconvolution and image reconstruction by using a Zeiss microscope (Axiovert 200M) with deconvolution capabilities
(Axiovision 4.1). The merge panels represent the deconvoluted images from the Alexa-Fluor 488 (green), Alexa-Fluor 568 (red), and DAPI signals. D.
Quantification of the immuno-fluorescence experiments. The percentage of cells containing aggresomes (black bars) and of aggresomes containing
p300 (gray bars) was calculated in mock treated (2) or MG132 treated (+) cells. E. Cos7 cells were mock treated (2; lanes 1 and 4) or treated with
MG132 (+; lanes 2, 3 and 5) and cell extracts were subjected to immuno-precipitation with a control antibody (lane 3) or with the anti-p300 antibody
(lanes 4 and 5). Immuno-precipitation reactions were divided into different aliquots and subjected to immuno-blot with anti p300 (top panel), anti-
HDAC6 (mid panel) or anti dynein antibodies (bottom panel), as indicated. Lanes 1 and 2 contains inputs levels of the indicated proteins.
doi:10.1371/journal.pone.0048243.g001
p300 Regulates the Fate of Misfolded Proteins
PLOS ONE | www.plosone.org 3 November 2012 | Volume 7 | Issue 11 | e48243
value (.0.001) (Figure 4A and Table S1). In an interesting
analogy, some of these C. elegans genes, the Abu family, were
isolated in metazoans carrying mutations that hamper the folding
capacity of the endoplasmic reticulum (ER) [23], a situation that
overwhelms cells with misfolded proteins in a manner similar to
that achieved with proteasome inhibitors. Based on these
similarities, we call this domain, p300 region Similar to Prion-
like Domains, or PSPD.
Several lines of evidence indicate that prion proteins contain
intrinsically disordered regions. For example, the yeast prion
proteins Ure2p and Sup35p contain a prion domain in their N-
terminus which is sufficient for prion formation and is intrinsically
disordered [24]. Similarly, toxic signaling due to the cellular PrPC
protein requires the intrinsically disordered N-terminal domain
[25,26]. Thus, we next studied the intrinsic disorder propensity of
both the full length p300 protein and of the PSPD (1514–2414), by
analyzing their compositional profiles. This analysis is based on the
important observation that amino acid compositions of ordered
and intrinsically disordered proteins are very different, with
disordered proteins being systematically enriched in so-called
disorder-promoting residues (A, R, G, Q, S, E, K, and P) and
depleted in order-promoting residues (W, Y, F, I, L, V, C, and N)
[27,28,29]. Composition profiling is based on the evaluation of the
(Cs1–Cs2)/Cs2 values, where Cs1 is a content of a given residue in a
protein of interest (p300 or its C-terminal domain), and Cs2 is the
corresponding value for the sample set of ordered proteins from
the public domain binding database, PDB [29]. Relatively to
typically ordered proteins, p300 and the PSDP are depleted in
major order-promoting amino acids (W, F, I, Y, V, and L) and are
enriched in some disorder-promoting residues, particularly Q, S,
and P (Figure 4B). Interestingly, both p300 and the PSPD have
low content of charged residues, being instead enriched in some
polar but non-charged residues. Figure 4C and Figure 4D
represent evaluation of disorder propensity in these proteins
studied by employed four disorder prediction tools of the PONDR
family. This analysis showed that full length p300 and especially its
C-terminal region are highly disordered. At the next stage, two
different algorithms were used to find disordered regions of p300
that can bind to specific partners, and potentially undergo the
disorder-to-order transitions as a result of this binding. Figure 4C
shows that p300 contains a large number of potential disorder-
based binding sites, a-MoRFs [30,31], and ANCHOR-indicated
binding sites (AiBSs) [32], which often completely or partially
overlap with each other. The presence of these sites is an
indication that the major function of the disordered p300 domains
might consist in providing an interaction platform with various
binding partners, a view supported by results presented later.
The PSPD Contains Significant Amount of Aggregation-
prone Regions
Several algorithms for predition of the aggregation-prone
regions within a protein of interest are available. Here, we utilized
two of such algorithms, FoldAmyloid (http://antares.protres.ru/
fold-amyloid/), and Zyggregator (http://www-vendruscolo.ch.
cam.ac.uk/zyggregator.php). These predictors use the knowledge
of the sequence of amino acids for the simultaneous estimation of
both the propensity for folding and aggregation and the way in
which these two types of propensity compete [33,34]. Application
of these algorithms in the early large-schale studies revelated that
the regions of a protein with a high intrinsic aggregation
propensity can be identified in a robust manner from sequence
only and also clearly showed that the structural context of such
regions in the monomeric protein prior the aggregation is crucial
for determining their actual role in the aggregation process
[33,34]. Of special interest is the early observation that the protein
regions with high expected probability of the formation of
backbone–backbone hydrogen bonds as well as regions with high
expected packing density are mostly responsible for the formation
of amyloid fibrils [33], especially if these regions are located within
the intrinscially disordered proteins/domains. The results of the
evaluation of the aggregation propensity of different region of
p300 by Zyggregator and FoldAmyloid are shown in Figures 4E
and 4F, respectively. This analysis revealed that the aggregation-
prone regions are predominantly located within the central and C-
terminal domains of p300. Furthermore, 18 of 38 amyloidogenic
regions predicted by FoldAmyloid are located within the PSPD,
whereas N-terminal domain (residues 1–900) contains just 6 such
regions. Longest aggregation-prone regions (residues 1733–1747
and 1783–1792) are also located in PSPD. Finally, according to
FoldAmyloid, of 900 residues in PSPD, 126 were included into the
aggregation-prone regions. In combination with the fact that
PSPD was predicted as mostly disordered domain, these
observations suggest that the p300 region similar to prion domains
play a crucial role in the aggregation behavior of this protein.
Figure 2. p300 co-localizes with a-synuclein, ubiquitin and
HDAC6 in brain of patients affected by Parkinson Disease.
Sections of midbrains or cortex from normal control patients (A), or
from patients by Parkinson Disease (B–E) were immuno-stained with
the anti-p300 (red) and a-synuclein (green, panels B,C), or with anti-
ubiquitin (green, panel D), or with anti-HDAC6 (green, panel E)
antibodies as indicated at the top of each panel. Different sections
from the same patients or from different patients were subjected to
analysis.
doi:10.1371/journal.pone.0048243.g002
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The PSPD is Encoded as an Alternatively Spliced Variant
and Promotes the Association with Aggresomes and with
Ubiquitinated Proteins
During the course of our analysis of p300 levels in cells, we
detected the presence of various p300 protein species with various
electrophoretic mobility (i.e., see Figure 5E). The difference in
the molecular weight of these p300 isoforms suggested that they
might represent alternatively spliced products. To explore this
possibility, we first interrogated the Aceview database at NIH,
which provides a curated and comprehensive collection of all
recorded mRNA sequences [35,36]. Analysis of the p300 gene
organization suggests the existence of at least 9 mRNA variants
(Figure 5A). Significantly, transcript b encodes a truncated
version of p300 lacking the N-terminus the CH1, CH2 and the
HAT domain, and encompassing almost entirely the PSPD region
from amino acids 1624 to 2414 (Figure 5B). The existence of this
complete and capped mRNA is supported by various clones and
can be seen at http://www.ncbi.nlm.nih.gov/IEB/Research/
Figure 3. Identification of the structural domain of p300 responsible for localization into aggresomes. A. Schematic representation of
the various p300 domains (see also text for further description). The three Cystein-Histidine-Rich domains, (CH1, CH2 and CH3), are delineated by
colored boxes. The bromodomain (Br) and histone acetylatransferase domains (HAT) are labeled by colored horizontal lines. Under the diagram, a
scheme of the p300 expression vectors and relative amino acid residues affected by deletions/mutations used for detection of p300 in aggresomes, is
shown. B. Quantification of the immuno-fluorescence experiments, showing the percent of cells containing p300 in aggresomes relatively to the total
number of cells expressing each of these deletion products. Cos7 cells were transfected with the vectors expressing p300 full-length, p300D30 or
p300-N, p300-D242–1737 or p300-CH3-CTD and the percentage of cells containing p300 in aggresomes was calculated from two separate
experiments. Representative immuno-fluorescence data from these experiments are shown in panel C. C. Cells were treated with MG132, and
subsequently stained for vimentin (red), or for p300 and then counterstained with DAPI (only shown in the merge panels). Arrows indicate the
position of aggresomes.
doi:10.1371/journal.pone.0048243.g003
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Figure 4. In silico analysis of the region of p300 responsible for the localization into aggresomes. A. Blast results of the region of p300
encompassing amino acid residues 1514 to 2414 showing representative similarities with the prion-like protein pqn-85 of C.Elegans. The results of this
search are displayed in more detail in table S1. Amino acid residues labeled in red designate identity, while the blue color outlines the Q and N
residues in the p300 or pqn-85 proteins. p300 has a 22% total content of Q/N in this region B. Compositional analysis of full length p300 (red) or of
the p300-CTD (green) in comparison with composition of typical ordered proteins. Compositional profile of typical intrinsically disordered proteins
from the DisProt database is shown for comparison (black bars). Positive bars correspond to residues found more abundantly in p300, while negative
bars show residues, in which p300 is depleted. This analysis shows that compared to ordered proteins, p300 is enriched in the disorder-promoting
p300 Regulates the Fate of Misfolded Proteins
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Acembly/av.cgi?db = human&term=EP300&submit =Go). The
alternative exon of transcript b is predicted to encode a protein
of 85 kDa with no sequence dissimilarity relatively to the main
p300 transcript. To gain further evidence for the existence of this
mRNA, we designed a combination of primers localized in the
alternative intron-exon junction (schematically shown in
Figure 5B). A mRNA product of expected size is detected in
Hek293 cells after reverse transcription using an oligo-dT primer
59 (Figure 5C). To then determine whether this mRNA generates
a protein product, cellular extracts derived from Hek293 untreated
or MG132 treated cells were first immuno-precipitated with the
anti-p300 antibody directed against the last C-terminal portion
(Ab-C20) (see strategy illustrated in Figure 5D). The products of
these immuno-precipitation reactions were then probed in
immuno-blot with an antibody raised against amino acid residues
2107–2283 (Ab-RW109; indicated as IB-1 in Figure 5D) or with
an antibody raised against the N-terminal region (Ab-N15;
indicated as IB-2). As shown in Figure5E, a p300 product of
lower molecular weight was detected and was strongly enriched in
MG132-treated cells in the IB-1 immuno-blot (left panel, indicated
by arrow), but not in the IB-2 IB (mid panel). Because the RW109
antibody recognizes the p300 C-terminus but does not interact
with the N-terminus or with the HAT domain, these results
demonstrate the existence of a p300 polypetide corresponding to
the PSPD.
To then assess the function of this alternatively spliced product,
we studied the activity of a large p300 fragment encoding amino
acids 1514–1922, which encompasses almost entirely the PSPD.
First, we asked whether the PSPD, per se, is able to promote
aggregation and localization into aggresome of a foreign protein
(Red Fluorescent Protein, RFP). As shown in Figure 6, in MG132
treated cells RFP alone was seen predominantly in the nucleus and
diffusely in the cytoplasm (Figure 6A). Expression of PSPD re-
localized RFP into disperse cytoplasmic inclusions in the absence
of MG132 (Figure 6B, compare panels 1 and 2 with panel 3).
Furthermore, in MG132 treated cells RFP-PSPD formed larger
aggregates that exhibited two different patterns of localization: it
either formed distinct and large aggresomes with a well-defined
collapsed vimentin ring (Figure 6C, panels 4 to 6); or it co-
localized, together with vimentin, in large inclusions that occupied
the cytoplasm and surrounded the nucleus (Figure 6D, 7 to 9).
Time-lapse video-microscopy performed in cells transfected with
RFP-PSPD demonstrated that this ring structure represents an
initial stage of aggresome formation, which ultimately leads to the
defined juxta-nuclear bodies (movie S1). These observations
demonstrate that the p300 PSPD accompanies all stages of
aggresome maturation, and suggest that p300 might be a
structural component of these organelles.
Misfolded proteins that accumulate in aggresomes are poly-
ubiquitinated. In keeping with the above results, and given the
previously shown association of p300 with ubiquitinated protein
species, we then asked whether the PSPD is responsible for driving
the interaction with ubiquitinated polypeptides. To test this, the
vector expressing the p300-PSPD tagged with a Flag-epitope was
expressed in Cos7 cells in the presence or absence of MG132, and
subjected to the immuno-precipitation with the anti-Flag antibody
followed by immuno-blot with anti-ubiquitin antibodies. More-
over, we used two additional constructs containing either the
TAZ2- or the ZZ- zinc fingers of p300. In the immuno-
precipitation reaction containing the PSPD and TAZ2 domain
of p300, but not the ZZ finger, multiple ubiquitinated polypeptides
were clearly detected (Figure 6E, compare lanes 1, 2 and 6 with
lanes 8 and 9). These species did not react with the anti-flag
antibody (Figure 6E, lanes 4 and 5; and lanes 10 to 12), thus
demonstrating that they do not correspond to ubiquitinated forms
of p300 itself, but rather reflect the p300 association with
ubiquitinated protein species. Therefore, within the PSPD, the
TAZ2 domain promotes the association with ubiquitinated
proteins.
The p300 PSPD Promotes Aggregation of TAU, of p53
and of p21/WAF
The presence of intrinsically disordered domains within a
protein enhances interaction interfaces, functional complexity, as
well as the propensity to associates promiscuously with other
disordered proteins [37,38]. Therefore, we first examined whether
p300 interacts with TAU, whose aberrant conformations and
aggregation hallmark Alzheimer’s disease and other neuropathol-
ogies referred to as tauopathies [39]. Co-localization of TAU and
endogenous p300 was detected in TAU typical cytoplasmic
filaments in approximately 10% of the cells expressing TAU
(Figure S3A and S3D, panel 3). Furthermore, transfection of
the p300 PSPD led to a change in the pattern of TAU distribution
in cells, with a significant increase in the percentage of cells
displaying TAU cytoplasmic aggregates (Figure S3B and S3D,
panel 6, and quantified in panel S3C). Indeed, in cells
transfected with control vector 30% of cells formed aggregates,
but almost all (approximately 80%) of cells co-transfected with the
PSPD displayed an aggregated pattern.
The tumor suppressor p53 has an intrinsically disordered
conformation and although is a predominantly nuclear protein, its
abnormal localization in the cytoplasm in a misfolded configura-
tion often in the form of inclusions, occurs in various tumors
[40,41,42]. The tendency to aggregate is increased by tumor
derived mutations of the p53 gene within the DNA binding
domain and depends, in part, upon their defective clearance [43].
residue C, H, M, Q, S, N, and P and is depleted in major order-promoting residues W, F, I, Y, V, L, A, R, D, E and K. Furthermore there is a low content of
charged residues, with enrichment in polar but non-charged residues. C–D. Evaluation of intrinsic disorder in the full-length p300 (C) and its C-
terminal domain (CTD), residues 1514–2414 (D). Four disorder prediction tools of the PONDR family were used (28–30): PONDRH VSL2B, which is
statistically better for proteins containing both structure and disorder; PONDRH VL3 which is better for proteins that are experimentally known to be
100% disordered or possess long disordered regions; PONDRH VLXT which is useful for predicting MoRFs, short disordered regions that become
structured when they interact with their binding partners; and PONDR-FIT a meta-predictor which is statistically not different from PONDRH VL3 for
fully disordered and fully structured proteins, and slightly better (1 std) than PONDRH VSL2 when both structured and disordered regions are present.
The dark gray lines are disorder predictions by PONDRHVLXT; the red lines represent results of disorder prediction by PONDRHVL3; the blue lines
show disorder predictions by PONDRHVSL2; whereas green lines correspond to the results produced by PONDR-FIT; light green shadows represent
standard errors of disorder prediction by PONDR-FIT. Locations of structured domains (CH1 domain, residues 323–423 (PDB IDs: 1L3E and 1P4Q);
bromo-domain, residues 1040–1161 (PDB ID: 3I3J); acetyltransferase domain (HAT), residues 1284–1669 (PDB ID: 3BIY); and TAZ2 domain, residues
1723–1836 (PDB ID: 3IO2) are shown by dark blue and cyan bars. Figure 4C and 4D show that these proteins are highly disordered, since their curves
are mostly located above 0.5, albeit they also contain ordered regions. Figure 4C also shows that p300 contains a large number of potential disorder-
based binding sites, a-MoRFs and ANCHOR-indicated binding sites (AiBSs) (29–30). Locations of a-MoRFs and AiBSs are shown as pink and dark cyan
bars at the bottom of plots.
doi:10.1371/journal.pone.0048243.g004
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These considerations led us to examine whether p300 affects p53
aggregation. First, we found that endogenous wild-type p53 co-
localized with p300 and with the 20S subunit of the proteasome in
cytoplasmic aggregates of Hek293 (Figure S3E and S3F), where
p53 accumulates due to the presence of adenoviral proteins E1a
and E1B [44]. Second, expression of the p300-PSPD was able to
direct p53 localization into aggregates that contain ubiquitin and
the 20S subunit of the proteasome (Figure 7A and 7B). These
results suggested that by inducing aggregation, p300 might
sequester p53 from proteasomal degradation. To further explore
this possibility and to rule out cell type-specific effects, we
transfected H1299 cells expressing wild-type p53 with various
p300 constructs (Figure 3). In H1299 cells p53 is predominantly
nuclear and transfection of the p300-D30 or of the p300-N did not
modify this pattern of localization (Figure S4A and S4B). By
contrast, expression of the p300-PSPD relocalized p53 into
disperse cytoplasmic aggregates in untreated cells and in large
cytoplasmic inclusions in cells treated with MG132 (Figure S4C
and S4D). Significantly, the knock-down of p300 in A549 cells
lowered p53 levels and prevented stabilization induced by MG132
(Figure 7C). Since p300 also interacts with other tumor
suppressors [43,45], including p21/Waf, we next asked whether
the PSPD can induce aggregation of p21 as well. As shown in
Figure S4E, while p21 dysplays a predominantly nuclear pattern
of localization, in cells expressing the p300-PSPD p21 was
relocalized into discrete cytoplasmic aggregates.
It has been recently shown that misfolded, tumor derived
mutant forms of p53 can aggregate in various tumor cell lines
correlating with enhanced oncogenic capacity [40,41,43]. Thus,
we expanded these experiments to ask whether p300 affects p53
mutant aggregation. We found that expression of the p300-PSPD
induced aggregation of two different tumor derived mutants,
p53H175R and p53G245R (Figure S5), while down-regulation of
p300 in TOV cells, that express endogenous p53H175R,
destabilized mutant p53 (Figure 7D).
These results suggest that via the PSPD, p300 can bring TAU,
p21 and p53 into cytoplasmic inclusions leading to aggregation
and at least in the case of p53, to stabilization.
p300 is Necessary for Segregation of Ubiquitinated
Proteins into Aggresomes and Promotes Survival during
Misfolded Protein Stress
We showed previously that p300 localizes into aggresomes, and
that expression of the PSPD leads to detection of intermediate
precursor forms of these organelles, suggesting that p300
participates in some aspect of aggresome formation and/or
clearance. To test this hypothesis, we first studied the extent of
aggresome formation in cells were p300 levels were down-
modulated. While the majority of A649 cells receiving a control
siRNA formed aggresomes, these structures were detected in only
a very small percentage of cells harboring the p300 siRNA (72%
versus 32% respectively) (Figure 7E and quantified in Figure 7F).
This was not due to down-regulation of HDAC6, which is essential
for the formation of these structures, because HDAC6 levels were
unchanged (Figure 7G). Furthermore, in cells where p300 was
down-regulated, there was an altered localization pattern of
ubiquitinated protein species, that remained dispersed in the
cytoplasm and failed to form typical aggregates as in control cells
(Figure 8A and B).
Aggresomes have cytoprotective effects during misfolded protein
stress [8]. This protective role has been attributed to the
segregation of misfolded and ubiquitinated proteins that prevents
them from exerting potential toxicity in the cytoplasm or in other
compartments of the cell. Therefore, we next investigated whether
p300 modulates cellular susceptibility to this response. A549 cells
were transfected with either the control or with the p300 siRNA
and subsequently were treated with MG132. We observed that
while MG132 treatment induced an arrest in the G2 phase of the
cell cycle in control transfected cells, cells where p300 was
inhibited with the specific siRNA were only modestly arrested in
G2 (Figure 8C). More significantly, in cells expressing p300, a
short-term treatment with MG132 for 12 hours followed by a
wash-out did not compromise cell viability, while cells effectively
depleted of p300 completely failed to recover after removal of the
drug (Figure 8D, indicated as MG132 w/o). Similar experiments
were next performed in p300 null mouse embryo-fibroblasts
(p3002/2MEF) [46], and identical results were obtained
(Figure 8E). To ensure that lack of viability is not due to a
general and non-specific hyper-sensitivity of cells lacking p300 to
all forms of stress, we assayed the sensitivity of p3002/2MEF to
heat shock (HS). This type of stress also induces misfolding and
denaturation of intracellular proteins, however, cells rely for
survival on the folding capacity of the ER and on de novo protein
synthesis [47]. Unlike in the case of proteasomal inhibition,
p3002/2 and wild-type MEF displayed similar rates of survival
during HS (Figure 8F). Thus, these results indicate that p300 acts
as a survival factor during the misfolded protein response due to
proteasomal stress.
Discussion
In this study we have shown that p300 possesses an
intrinsically disordered domain, which is capable to direct
p300 localization into cytoplasmic aggregates. Intriguingly, this
domain shares similarities with prion-like proteins including the
Figure 5. An alternatively spliced product of p300 encompasses the PSPD region and is enriched in MG132 treated cells. A.
Schematic representation of the alternative exons and spliced variants of p300. These data were extracted from the Aceview database (31,32). B.
S t r u c t u r e o f t h e p r e -me s s e nge r mRNA ( v a r i a n t b , h t t p : / /www . n c b i . n lm . n i h . g o v / I E B / R e s e a r c h / A c emb l y / a v .
cgi?db=human&term= EP300&submit =Go). This complete CDS mRNA is 3297 base pair long. It is predicted to encode a protein of 85 kDa
which is identical in sequence to the full length p300, encompassing amino acid residues 1624 to 2414. To gain evidence for the presence of this
mRNA, we employed a combination of primers localized in the alternative exon (depicted in panel B). As shown in panel C (left panel), an product of
expected size is detected in Hek293 cells after reverse transcription using oligo-dT primer 59. This PCR product was sequenced and matched the
sequences of the p300 mRNA. The right panel in C, shows a control amplification reaction with GADPH primers. The position of the amplified
products relatively to the 100 bp ladder is indicated. D–E. Detection of a p300 polypeptide lacking the N-terminal region and encompassing the
p300 C-terminus. Panel D illustrates the strategy employed for these experiments. Cellular extracts derived from Hek293 untreated or MG132 treated
were equalized for protein concentration, and first immuno-precipitated with the anti-p300 antibody directed against the C-terminal region (C20, SC).
The product of these immuno-precipitation reactions were then probed in immuno-blot with an antibody directed against either amino acid residues
1572–2371 (RW109; indicated as IB-1), or with antibody raised against the N-terminal region (N15; indicated as IB-2). As shown in panel E, a p300
product of compatible size is detected and enriched in MG132 treated cells in the IB-1 immuno-blot (left panel), but not in the IB-2 IB (mid panel). The
right panel shows the inputs levels of cell extracts employed for the immuno-precipitations with an equal actin signal. Arrows indicate the presence
of p300 full length or of the PSPD.
doi:10.1371/journal.pone.0048243.g005
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Abu family of genes of C. Elegans [23]. Abu genes were found up-
regulated in worms with hampered ER activity that leads to an
overload of incorrectly folded proteins. In a compelling analogy,
in C. Elegans Abu genes are required for the ability to cope with
such surplus of misfolded proteins, and in mammalian cells
p300 functions as a pro-survival factor when aberrant proteins
accumulate as a result of proteasome block. Thus, like Abu
genes, p300 helps cells deal with stress arising from accumu-
lation of misfolded proteins.
Proposed Model of Action of the p300 PSPD
Although the p300 PSPD is not a canonical prion domain, it is
worth discussing several of its characteristics that insinuate
functional analogies with prion-like regions. Prion domains have
a particularly high content of glutamine and asparagine residues
Figure 6. The p300 PSPD is sufficient for aggresome localization. A–D. Cell transfected with the vector expressing RFP alone and treated
with MG132 (panel A), or transfected with the RFP-PSPD (panels B–D) were mock treated (B), or treated with MG132 (C–D) and subsequently stained
for vimentin (green). Panels C and D contain two representative fields of cells transfected with RFP-PSPD. Arrows indicate the position of aggregates
formed in the absence (panel B) or in the presence of MG132 (C and D). E. Interaction of p300 with ubiquitinated protein species. The epitope-
flagged vector expressing the PSPD (lanes 1–5), or the TAZ2 (lanes 6,7 and 10,11) or the ZZ (lanes 8,9 and 12,13) were transfected in Cos7 cells. Cells
were left untreated (2) or treated with MG132 (+), cell extracts were immuno-precipitated with the anti-Flag antibody (lanes 1,2; and 6-to-9), or with a
control isotype matched antibody (lane 3) and the products of these immuno-precipitation reactions were probed with ubiquitin antibodies as
indicated at the bottom of each panel. Alternatively, the anti-Flag immuno-blot on total cell extracts shows the total amount of p300 proteins present
in these reactions, which were derived from approximately 1/50 of total extracts.
doi:10.1371/journal.pone.0048243.g006
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and induce self- and hetero-aggregation [48]. The PSPD possesses
an unusually high Q/N content (22%), it forms aggregates, -
suggestive of self-aggregation-, and is also capable of inducing
aggregation of TAU and of p53. Furthermore, the in silico analysis
revealed that this p300 domain is enriched in the aggregation-
prone regions (Figure 4E and 4D). Intriguingly, recent evidence
Figure 7. A-B. The p300-PSPD brings p53 in cytoplasmic aggregates. Hek293 cells were co-transfected with a vector expressing epitope
tagged GAL4-PSPD and p53. In panel A cells were stained with an antibody recognizing p53 (polyclonal goat, blue), with anti-GAL4 antibody
(monoclonal mouse, green), and with the anti-20S proteasome polyclonal antibody (red). The white or red arrows indicate cell expressing or not
p300-PSDP. Note that p53 forms inclusions only when p300-PSDP is expressed. In panel B, a vector expressing GFP-p53 was employed to
demonstrate co-localization with the 20S subunit of the proteasome (red). Merged images are shown in the last right panel. p53 did not form
inclusions with control vector alone (not shown). C. A549 cells e were transfected with scramble, control siRNA (lanes 1 and 3), or with the p300
specific siRNA (lanes 2 and 4). Seventytwo hours after transfection cells were treated with vheicle (lanes 1, 2) or with 20 mM MG132 (lanes 3,4) for 16
hours, and cell extracts were prepared. Total levels of p53 and Hsp70 are shown. D. TOV cells expressing the tumor-derived p53 mutant, p53R175H,
were transfected with scramle or p300 shRNA as described in C, and cell extracts derived from these transfection were probed for p53, p300 and
actin. E–F. The knock-down of p300 impairs aggresome formation. E. A549 cells were transfected with scramble siRNA or with the p300
specific siRNA. Cells were grown on glass cover slips, treated with MG132 for 16 hours, and then probed with the anti-p300 specific polyclonal
antibody (red), or with the monoclonal antibody directed against vimentin (green). Representative fields are shown in D. F. Quantification of the
experiments shown in E. Aggresomes were counted in cells transfected with scramble- or p300-specific siRNA and percentages are shown at the top
of the bars. Black and gray bars indicates the percentage of cells displaying aggresomes in the presence of control or p300 siRNA. The presence of
aggresomes was assessed based on the presence of the vimentin ring. Results are representative of two independent experiments, each performed in
duplicate. G. Assessment of HDAC6 expression levels in A549 cells transfected with control- and p300-siRNA.
doi:10.1371/journal.pone.0048243.g007
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demonstrates that some co-repressors and components of the
transcriptional machinery, such as SWI/SNIFF and Cyc8 contain
aggregation prone domains and can replicate as prions in yeast
[49,50]. Moreover, there are other examples of proteins charac-
terized by glutamine rich regions that confer high propensity to
aggregation, and thus mimic aggregation prone elements of prions
even though they are devoid of infectious properties. The disease-
associated huntingtin protein possesses an extended glutamine
tract that drives its aggregation in Hungtington Disease. Curiously
CBP, but not p300, displays a poly-glutamine tail in its C-terminal
region that allows it to interacts with huntingtin in typical inclusion
bodies [51]. However, unlike aggregates formed by p300 that
Figure 8. Effects of p300 on the misfolded protein response. A. A549 cells were transfected with scramble siRNA or with the p300 specific
siRNA as described previously, and stained with the anti-ubiquitin (green) or anti-vimentin (red) antibody. The percentage of cells containing
ubiquitin aggregates is quantified in panel B. C. A549 cells were transfected with the scramble- or p300-specific siRNAs were mock treated or treated
with MG132 for 16 hours, then harvested for flow cytometry. Panel C shows the Propidium Iodide profiles, and percentages of cells in the G1 or G2
phases of the cell cycle are indicated at the top of each relative peak. D. A549 cells transfected with scramble (black bars) or with the p300 siRNAs
(gray bars), were treated with MG132. In one set of samples MG132 was washed out after 12–14 hours of treatment (indicated as MG132 w/o) and
cells were allowed to recover for about four days, at which time they were counted. Alternatively, cell growth was monitored for the same period of
time in the presence of MG132 (indicated as MG132 on). Error bars represent standard deviations. E–F. Control (wt) or p300 null mouse embryo
fibroblasts (MEF) were mock treated or treated with MG132 for 16–24 hours (panel E), or alternatively, subjected to Heat Shock (HS, panel F) by
incubating the cells at 40uC for two hours. Cells were allowed to recover from MG132 treatment or HS for 24–48 hours and were counted. Cell
viability was assessed with trypan blue exclusion.
doi:10.1371/journal.pone.0048243.g008
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reside in the cytoplasm, inclusion bodies formed by CBP are
nuclear. Thus, both p300 and CBP have aggregation-prone
elements, however they form aggregates in different sub-cellular
compartments.
What are then, the physiological functions of these aggregation
prone domains in p300 and CBP, why do transcription activators
and co-repressors contain such domains, and why such domains
aggregate in some contexts and not in others? Aside from post-
translational modifications and protein-protein interactions, sev-
eral studies have demonstrated the importance of metal ions in
protein folding and aggregation, with zinc playing a very
important role in this respect [52,53]. The three-dimensional
NMR structure of several portions of p300 or CBP has been
determined. The NMR structure of the TAZ2 zinc-finger, for
example, has shown that the spectrum of this domain at low
concentration of zinc is poorly dispersed and has narrow line-
widths, an indication that it is unfolded [54]. By contrast, the
spectrum in the presence of three equivalents of zinc is typical of a
well-folded protein. At low concentration of zinc, the cysteine
residues are exposed to solvent in order to avoid intra-molecular
disulfide bridges. In the model shown in Figure 9A, we propose
that these exposed cysteine and histidine residues could form inter-
chain aggregates stabilized by disulfide bridges between unligated
cysteine residues as well as by inter-chain hydrogen bonds among
the side chains of glutamine and asparagine residues, which are
present throughout the CH3 and PSPD sequence. In fact, a total
of 22% Q/N is found in the C-terminus of p300, and 17% are
present in TAZ2 finger alone, an amount lower than typical
prions, but certainly highly unusual compared to other zinc
fingers. These intra-molecular interactions could contribute to
aggregation and stabilize self- and hetero- aggregates depending
upon zinc availability. It is therefore attractive to speculate that in
the context of transcription, changes in the aggregation state of this
region and its misfolding might expand the promiscuity of p300’s
binding repertoire, leading to local aggregation on chromatin of
factors required for activation or repression. In the cytoplasm, this
domain might be involved in the interaction with various
misfolded and ubiquitinated proteins and in their segregation into
aggregates.
Thus, an important question for further studies will be to
determine the molecular mechanisms that regulate the sub-cellular
partitioning of p300. In keeping with the existence of an
alternatively spliced variant of p300 encompassing the PSPD,
and given that the p300 N-terminus contains the nuclear
localization signal [55], alternative splicing could at least in part
dictate p300’s subcellular distribution and also its tendency to
aggregate in physiological or in pathological conditions.
A Dual Role of p300 in Regulation of the Activity of p53
We have further shown that endogenous p53 and p300
colocalize in cytoplasmic inclusions and in aggresomes. Indeed,
these inclusions contain ubiquitin, the 20S subunit of the
proteasome and also cytoskeletal proteins such as vimentin. We
have also shown that the PSPD of p300 is sufficient for inducing
the formation of aggregates and to relocalize p53 in such
structures. Interestingly, the CH3 within the PSPD domain
contains, in addition to a p53-binding site, also a domain of
interaction for the viral oncoproteins SV40 Tag and Adenoviral
E1a, and we observed that in some cells expressing these viral
proteins, such as in Hek293 cells, aggregates containing p53 and
p300 form spontaneously, in the absence of proteasome inhibitors.
Thus, it is possible that viral oncogenic pathways exploit this
domain of p300 to mimic a misfolded protein response, and to
seclude p53 into cytoplasmic aggregates thereby rendering it
inactive. This novel activity of p300 that can be potentially
relevant to oncogenic transformation.
The N-terminal region of p300 has been shown to possess E4,
ubiquitin-chain elongating activity that induces poly-ubiquitina-
tion and degradation of p53 [19]. Indeed, the fact that p300
functions to destabilize wild-type p53 in certain conditions is
supported by multiple lines of evidence, including demonstration
that p300 enhances MDM2-mediated destruction of p53 [19,20].
Thus, p300 might play a dual role in the stability of p53 (illustrated
in Figure 9B). Specifically, on one side, p300 might promote p53
degradation via its N-terminal activities, on the other side, the C-
terminal region of p300 might lead to p53 stabilization. Thus, the
regulated action of different regions of p300 might dictate whether
p53 should or should not be destined for disruption, depending
upon its configuration, cellular context and post-translational
modifications. Importantly, at least three interaction sites for p53
have been identified by us and by other laboratoties, one in the N-
terminus, a second in the acetyl-transferase domain, and a third in
the C-terminus of p300 [16]. Thus, does p53 differentially
interacts with these p300’s domains in a signal or cell type-
dependent manner? Further studies should address this question.
p300 as an Integrator of Cellular Responses to Misfolded
Protein Stress
We have further shown that p300 acts as a protective survival
factor in the misfolded protein response. Thus, consistent with
data from other groups [7,8], our own data imply that aggresomes
have a pro-survival and chemo-protective effect. It is likely that the
sensitivity of cells to misfolded protein stress is determined by the
integration of p300 multiple activities. Particularly, the positioning
onto aggresomes of p300, a protein also endowed with transcrip-
tional functions, might represent a strategy through which cells
transduce stress signals arising from accumulation of misfolded
proteins into proper adjustments of the cell cycle, a view consistent
with results shown here. Additionally, given that proteasome
inhibitors and drugs that affect protein-triage decisions have enter
clinical testing in cancer and neurdegeneration [15,55], our data
may foster the development of novel molecules that, by targeting
different p300 domains, affect life and death decisions in various
pathogenic conditions.
Methods
Tissue Culture, Cell Treatments and Reagents
H1299 lung carcinoma cells, H1299 lung cancer cell line, A549
human lung epithelial cells, Hek293 human embryonic kidney
cells, and COS7 transformed African Green Monkey kidney
fibroblasts were obtained from ATCC or from the Tissue Culture
Core Facility of Georgetown University. H1299 cells expressing
wild-type p53, or p53 mutants at position R175H or G245A have
been described previously [56,57]. Cells were grown in Dulbecco’s
modified Eagles’s Medium (DMEM) supplemented with 10% (v/v)
fetal bovine serum, L-glutamine (5 mM), penicillin (100 U/ml),
and streptomycine (100 mg/ml). Vectors for the tetracycline
inducible system were purchased from Invitrogen and generation
of cells lines was achieved accordingly to manufacturer instruc-
tions. Transfections were performed by using Lipofectamine
(Invitrogen) or FuGene 6 (Roche) reagents.
RT-PCR. The primers for detection of the p300 alternatively
spliced product were designed based on the sequences of the
alternative exon provided by theAceview database and were as
follows: Forward: 59- ATGACAGAGCGAGGCCCTGTCT-39;
Reverse: 59-CCATTGGTTTTCCGTTTGCAACCCT-39. RT-
PCR was performed with QIAGEN OneStep RT-PCR Kit.
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Immuno-blotting and Immuno-precipitations
For immuno-blotting cells were extracted in TBS Buffer
(1%Triton X-100; 50 mM Tris-HCl pH 7.4; 150 mM NaCl;
1 mM EDTA). Cells were extracted in Buffer A (20% Glycerol;
40 mM Tris HCl pH 7.9; 0.4 mM EDTA; 0.2% Tween 20;
100 mM KCl), supplemented with protease inhibitors. Protein
extracts were combined with the indicated antibody, precipitated
with immobilized protein A beads (Pierce), and subjected to SDS-
PAGE, followed by transfering to PVDF membranes (Milipore).
Chemiluminescence was performed with the WestPico system
(Pierce). The primary antibodies used for immunoblotting were:
p300 [N15 and C-20, Santa Cruz Biotechnology (SCBT)]; a-
tubulin (B-5-12, Sigma); FLAG (M2, Sigma); GRP78 (C20,
SCBT); dynein, intermediate chain (74-1, SCBT); ubiquitin
Figure 9. A. Proposed model for aggregation of the TAZ2 domain depending upon the concentration of zinc. See also text for
explanation. The 1H-15N HSQC spectrum of the TAZ2 apoprotein at low concentration of zinc is poorly dispersed and has narrow line-widths. In low
concentration of zinc, the cysteines residues in the fingers will be exposed to solvent in order to avoid intramolecular disulfide bridges. These
exposed cysteines with histidines from two chains could interact with zinc and form interchain aggregates. Additional interchain stability could be
obtained by forming interchain disulfide bridges between unligated cysteines residues as well as by forming two interchain hydrogen bonds among
the side chains of glutamine and asparagine residues which are present throughout the sequence. A schematic representation of intermolecular
aggregation is shown. B. Based on data presented here, and in keeping with previous studies that implicated p300 as an E4-ubiquitin ligase, as well
as with evidence that p53 is activated by p300 when acetylated, we envision that p300 plays versatile and multiple effects on p53 activity. p53
interacts with at least three sites on p300, as indicated in the Figure, and each interaction site leads to different outcomes. While the interaction with
the N-terminus serves to promote degradation of natively folded forms of p53 and to maintain low p53 levels in normal cells, the p300 PSPD brings
p53 into cellular aggregates.
doi:10.1371/journal.pone.0048243.g009
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(P4D1, SCBT and 13-1600, Zymed); p53: [Ab-1 (pAb421), Ab-3
(pAb240) and Ab-6, (DO-1), Calbiochem; FL393, SCBT); hsp70
(W27, SCBT); HDAC6 (H-300 polyclonal rabbit; and D11
monoclonal mouse, SCBT).
Recombinant Plasmids
For the generation of RFP-fusion proteins the p300 target
sequence was PCR amplified with primers that incorporated an
XhoI and KpnI restriction site into the 59 and 39 end of each
amplicon, respectively. The resulting amplicons were then
digested with XhoI and KpnI and cloned in frame with the
pDsRed fluorescent protein in the pDsRed-Express-C1 vector (BD
Biosciences). The primers employed were: RFP-CH3 (p300
sequence 1514–1922) 59-aattgctcgaggcgaagaaagcattaaggaactgg-39
and 59-aattcggtacctgggggccctggaagg-39; RFP-ZZ (p300 sequence
1620–1730) 5-aattgctcgaggcccctgcgatctgatggatg-39 and 59-aattcgg-
taccagaatcgcctgggctctgg-39; RFP-TAZ2 (p300 sequence 1710–
1820) 59-aattgctcgaggccttggcttagatgatgagag-39 and 59-aattcgg-
taccgtgctgcagctgttgctgc-39.
Indirect Immuno-fluorescence
Cells were plated on glass cover slips, treated with 5 uM of
MG132 for 16 hr or vehicle (DMSO), then fixed with 4%
paraformaldehyde in PBS and permeabilized with 0.1% Triton X-
100 in PBS for 10 min, followed by incubation with blocking
solution (1% BSA in PBS). All antibodies were diluted in blocking
solution. The antibodies employed for IF were: p300 (N15 or C20,
SCBT); Vimentin (monoclonal-V9, polyclonal-H84, SCBT); p53
(monoclonal mix of Ab1 and Ab6, Calbiochem); Ubiquitin
(monoclonal mix of P4D1 and 13–1600, SCBT and Zymed,
respectively); GRP78 (C20, SCBT). After incubation with primary
antibodies cells were incubated with the appropriate secondary
antibodies: donkey anti-mouse or anti-rabbit Alexa488 and
Alexa566 fluoro-conjugated antibodies (Molecular Probes, Invi-
trogen). The cover slips were washed with PBS, post-fixed with 4%
parformaldehyde and nuclei were stained with DAPI and then
mounted on slides with ProLong Gold anti-fade reagent (Invitro-
gen). Images were captured with an Axiovert 200 M fluorescence
microscope (Zeiss), equipped with AxioCam MRm camera. The
Z-stack images data obtained with 40x, 63x or 100x oil immersion
objectives were processed and subjected to deconvolution with the
Axio Vs40 software (Zeiss).
Small Interfering RNAs
All the siRNA employed in this study were synthesized by
Ambion. CBP: Sense: GGAAUAGGAAAUGUGAGCGtt; An-
tisense: CGCUCACAUUUCCUAUUCCtg. p300: Sense:
AACCCCUCCUCUUCAGCACCA; antisense: UGGUGCU-
GAAGAGGAGGGGUU. For siRNA treatments, proliferating
cells were treated with each siRNA (50–100 nM) reagent in
serum-reduced Opti-MEM medium using Lipofectamine reagent
(Invitrogen). Cells were incubated in the presence of siRNA for
at least 72 hours after which time MG132 (Calbiochem) was
added.
Human Brain Specimens
Paraffin imbedded postmortem human brain sections from
Parkinson’s disease (PD) and non-PD control (normal aging)
patients, were from Neuropathology Lab, Johns Hopkins
University School of Medicine (Baltimore, MD) and New York
Brain Bank (NYBB) at Columbia University (New York, NY).
Immunohistochemistry of Human Brain Sections
Paraffin imbedded postmortem human brain sections were
subject to de-paraffinization, antigen retrieval, and melanin
bleaching prior to blocking and primary antibodies incubation.
In brief, the sections were de-paraffinized at 60uC for 1 h followed
by Xylene delipidation and decreasing ethanol concentrations
(100%–70%) for re-hydration. Antigens were retrieved with
sodium citrate buffer incubation at 95uC fro 20 min. Melanin
deposition of the human midbrain was bleached by 30 min
incubation in 0.2% potassium manganate (KMnO4) and followed
by 2 min incubation in hydrobromic acid water (3:1). The sections
were blocked in 4% normal goat serum (NGS) in 16PBS with
0.1% Tryton-X-100 at room temperature (RT) for 1 h. The
dilutions of the primary antibodies were as follows: for p300
(1:250; C20 from Santa Cruz); alpha-synuclein (1:100; monoclo-
nal, Abcam); HDAC6 (D11; 1:100); anti-ubiquitin (1:100;
monoclonal mix). The antibodies were mixed and diluted in
2%NGS/0.02% NaN3/16PBS, and sections were incubated at
4uC overnight. Following washes, the sections were incubated with
mixture of secondary antibodies Alexa FluorH 594 goat anti-rabbit
IgG (1:100) and Alexa FluorH 488 goat anti-mouse IgG (1:100) in
2%NGS/0.02% NaN3/16PBS at RT for 2 h. Sections were
washed in 16PBS and cover glassed with ProLong Gold mounting
media (Molecular Probe/Life technologies). Fluorescent-labeled
human brain section images were acquired with Carl Zeiss
AxioPlan 2 fluorescent microscope with AxioVision Rel.4.8
software.
Compositional Profiling
To gain insight into the relationships between sequence and
disorder, the amino acid compositions in different data sets were
compared using an approach developed for visualizing the
amino acid composition biases in IDPs. The fractional
difference in composition between a given set of the analyzed
cytoplasmic sequences, intrinsically disordered proteins, and a
set of ordered proteins was calculated for each amino acid
residue. The fractional difference is calculated as (Cs1–Cs2)/Cs2
values, where Cs1 is a content of a given residue in a protein of
interest (p300 or its C-terminal domain) and Cs2 is the
corresponding value for the sample set of ordered proteins
from PDB [29]. Positive and negative values indicate residues in
a given set that have more and less order, respectively.
Confidence intervals were estimated using per-protein boot-
strapping with 1000 iterations.
Disorder Prediction
The intrinsic disorder propensities of the analyzed proteins
were evaluated by four different disorder predictors of the
PONDR family. The first one is PONDRH VL-XT [58], which
applies various compositional probabilities and hydrophobic
measures of amino acid as the input features of artificial neural
networks for the prediction. Although it is no longer the most
accurate predictor, it is very sensitive to the local compositional
biases. Hence, it is capable of identifying potential molecular
interaction motifs. The second and third predictors are
PONDRH VSL2B [59], which is suitable for accurate evalua-
tion of short and long disordered regions, and PONDRH VL3
[60], which is suitable for finding long disordered regions. The
last tool is a meta-predictor PONDR-FIT that combines six
individual predictors, which are PONDRH VL-XT, VSL2, VL3,
FoldIndex, IUPred, and TopIDP. This meta-predictor is
moderately more accurate than each of the component
predictors [61].
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Molecular Recognition Feature (MoRF) and ANCHOR
Analysis
Being defined as a short order-prone motif within a long
disordered region and being able to undergo disorder-to-order
transition during the binding to a specific partner, Molecular
Recognition Feature (MoRF) usually has much higher content
of aliphatic and aromatic amino acids than disordered regions
in general. Due to these peculiarities, MoRF regions are
frequently observed as sharp dips in the corresponding plots
representing per-residue distribution of PONDRH VL-XT
disorder scores. Hence, based on the PONDRH VL-XT
prediction and a number of other attributes, the MoRF regions
can be identified [30,31]. In addition to MoRF identifiers,
potential binding sites in disordered regions can be identified by
the ANCHOR algorithm [32]. This approach relies on the
pairwise energy estimation approach developed for the general
disorder prediction method IUPred, being based on the
hypothesis that long regions of disorder contain localized
potential binding sites that cannot form enough favorable
intrachain interactions to fold on their own, but are likely to
gain stabilizing energy by interacting with a globular protein
partner. Here we are using the term ANCHOR-indicated
binding site (AIBS) to identify a region of a protein suggested by
the ANCHOR algorithm to have significant potential to be a
binding site for an appropriate but typically unidentified partner
protein.
Supporting Information
Figure S1 A. H1299 cells were mock treated (A) or treated with
5 mM MG132 for 16 hours (BC) and cells were stained with a
monoclonal mix of anti-ubiquitin, anti-p300, or anti-vimentin
monoclonal as indicated in each panel. The arrows indicate the
position of representative aggresomes. B. Human embryonic
kidney carcinoma cells Hek293 cells were stained for p300 (green),
and vimentin, as indicated at the top of each panel.
(TIF)
Figure S2 Detection of p300 in cytoplasmic inclusions in
the absence of MG132 treatment. A. Untreated or MG132
treated Cos-7 cells grown on coverslips were stained with anti-
vimentin and anti-CBP (C22) antibodies.
(TIF)
Figure S3 The p300-PSPD brings TAU in cytoplasmic
aggregates. A. Co-localization of endogenous p300 and TAU.
Cos-7 cells were transfected with the vector expressing TAU and
24 hours after transfection cells were stained with the polyclonal
antibody directed against p300 (C20, red, 1) and with a
monoclonal antibody recognizing TAU (green, 2). In a parallel
set of experiments, cells were co-transfected with the RFP-PSPD
and TAU expressing vectors (B), and stained as described in A.
The white rectangle in panels A and B demarks areas of co-
localization of p300 with TAU tangles (3) or with aggregates (6).
These areas are enlarged in panel D. C. Quantification of
experiments shown in panel B. Cells with no aggregates (gray
bars), and cells with aggregates (black bars) were counted in the
presence (+) or absence (2) of the p300-PSPD. Numbers
represents average percentage of cells. E-F. p300 and p53 co-
localize in cytoplasmic aggregates. Hek293 cells were plated
on glass coverslips and stained with the p53 monoclonal antibody
(red) and the p300 polyclonal antibody (green) (panel E); or with
the p53 monoclonal antibody and a polyclonal antibody
recognizing the 20S subunit of the proteasome (F). Arrows
indicate inclusion bodies in cells where p53, p300 and the 20S
proteasome co-localize. Approximately 60% of Hek293 cells
display these inclusions.
(TIF)
Figure S4 The p300-PSPD brings p53 and p21/WAF in
cytoplasmic aggregates. A–D. H1299 cells expressing tetra-
cycline-inducible p53 protein [56], were transfected with different
p300 mutants previously described in Figure 3, specifically with
the p300-D30 (A), p300-N (B) and p300-PSPD (C–D). Twenty
four hours after induction of p53 via tetracycline addition, a set of
cells transfected with the p300-PSPD were treated with MG132
(D), then cells were fixed and stained for p53 and p300. In panel C
and D, aggregates forming in cells expressing both p300 and p53
are indicated by white arrows. Red arrows indicate cells expressing
p53 but not the p300-PSPD.
(TIF)
Figure S5 The p300-PSPD promotes p53 mutant aggre-
gation. H1299 cell lines expressing p53G245A (panel A and B),
or p53R175H (panel C) [57], were seeded on glass cover-slips and
were transfected with RFP or with RFP-PSPD. After transfection
cells were stained with the anti-p53 antibody (FL393). Note the
nuclear pattern of localization of the p53 mutants in cells not
expressing the p300-PSPD. The white rectangles mark cells co-
expressing p300 and p53 and containing aggregates, which are
enlarged at the right of the merge panel.
(TIF)
Table S1 Similarity between the p300 region comprised
between amino acid 1688 to 1214 and various proteins
containing prion-like domains in C. elegans (pqn and
Abu family), and other species. All sequences found had a
blast e-value above 0.001.
(DOCX)
Movie S1 Dynamics of aggresomes in the presence of
RFP-p300-PSPD. Cells were transfected with the vector
expressing RFP-p300-PSPD, plated onto Lab-Tek II Chambered
coverglasses System dish, and then treated with 5 mM MG132.
The dishes were placed in a temperature-controlled stage at 37uC
on an inverted microscope (Nikon Eclipse TE300) in a 5% CO2
atmosphere, and subjected to time-lapse video microscopy. Images
were collected using a 40x lens, with a filter set for DsRED
(excitation 545 nm, dichroic 570 nm, emission 620 nm), and a
Hamamatsu Orca-ER, monochrome cooled CCD camera. Images
were taken at 15 min intervals for 16 h with MetaMorph Imaging
system, and were then assembled into QuickTime movies.
(WMV)
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